Back

Pulmonary arterial hypertension associated with congenital heart disease: real-world analysis of clinical characteristics, treatment patterns and outcomes from EXPOSURE

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Pulmonary hypertension around the real world Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Maria Pilar Escribano Subias

12th of October University Hospital, Madrid (Spain)

4 More presentations in this session

Presentation thumbnail
Characterisation of pulmonary arterial hypertension patients with cardiovascular comorbidities treated with selexipag: real-world evidence from the EXPOSURE study
Professor S. Soderberg (Umea, SE)
Abstract Slides Video
Presentation thumbnail
Incident pulmonary hypertension in 13,448 cases investigated with repeat echocardiography: insight from the national echo database of australia (NEDA)
Professor S. Stewart (Fremantle, AU)
Abstract Slides Video
Presentation thumbnail
Concomitant initiation of combination therapy with macitentan and tadalafil in pulmonary arterial hypertension (PAH) patients with comorbidities: Real-world data from OPUS and OrPHeUS
Professor R. Channick (Los Angeles, US)
Abstract Slides Video
Presentation thumbnail
Paediatric pulmonary arterial hypertension following congenital heart defect repair: enhanced risk stratification and outcomes in a national cohort
Doctor A. Constantine (Birmingham, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary hypertension around the real world

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Exploring and managing pulmonary hypertension in congenital heart defects: a challenging path
thumbnail
Congress Presentation
Adults with congenital heart disease and pulmonary arterial hypertension: Quantitative assessment of haemodynamic parameters under disease targeting therapy - A retrospective multicentre analysis
thumbnail
Congress Presentation
Evaluating the safety and long-term efficacy of triple vasodilator therapy for pulmonary arterial hypertension associated with congenital heart disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources